These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22703608)

  • 1. A case of paliperidone-palmitate-induced tardive dyskinesia.
    Lally J; Byrne F; Walsh E
    Gen Hosp Psychiatry; 2013; 35(2):213.e5-7. PubMed ID: 22703608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tardive dyskinesia induced by a switch from haloperidol depot to paliperidone palmitate.
    Hsu CY; Lin YH; Shen YC
    J Neuropsychiatry Clin Neurosci; 2013; 25(4):E46-7. PubMed ID: 24247889
    [No Abstract]   [Full Text] [Related]  

  • 3. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.
    Citrome L
    Int J Clin Pract; 2010 Jan; 64(2):216-39. PubMed ID: 19886879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.
    Owen RT
    Drugs Today (Barc); 2010 Jul; 46(7):463-71. PubMed ID: 20683501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
    Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
    J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
    J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral-paliperidone-induced tardive dyskinesia: a case report.
    Wei HT; Lai YW; Chen MH; Chen YS
    Gen Hosp Psychiatry; 2012; 34(5):578.e5-6. PubMed ID: 22154659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.
    Alphs L; Benson C; Cheshire-Kinney K; Lindenmayer JP; Mao L; Rodriguez SC; Starr HL
    J Clin Psychiatry; 2015 May; 76(5):554-61. PubMed ID: 25938474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
    Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
    Pandina GJ; Lindenmayer JP; Lull J; Lim P; Gopal S; Herben V; Kusumakar V; Yuen E; Palumbo J
    J Clin Psychopharmacol; 2010 Jun; 30(3):235-44. PubMed ID: 20473057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tardive Tourette-like syndrome in a patient treated with paliperidone.
    Fountoulakis KN; Panagiotidis P
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E35-6. PubMed ID: 22231343
    [No Abstract]   [Full Text] [Related]  

  • 13. [Utility of quetiapine in tardive dyskinesia].
    Navarro Pacheco BV; Montejo González AL; Martín Carrasco M
    Actas Esp Psiquiatr; 2003; 31(6):347-52. PubMed ID: 14639511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.
    Kramer M; Litman R; Hough D; Lane R; Lim P; Liu Y; Eerdekens M
    Int J Neuropsychopharmacol; 2010 Jun; 13(5):635-47. PubMed ID: 19941696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A change from risperidone long acting injection to paliperidone palmitate in an elderly patient--a cautionary tale.
    Singh D; Williams O
    Aust N Z J Psychiatry; 2012 Feb; 46(2):176-7. PubMed ID: 22311537
    [No Abstract]   [Full Text] [Related]  

  • 16. Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone.
    Perry R; Wolberg J; DiCrescento S
    Am J Health Syst Pharm; 2012 Jan; 69(1):40-3. PubMed ID: 22180550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catatonia and encephalopathy associated with paliperidone palmitate.
    Coffey MJ
    J Clin Psychopharmacol; 2012 Apr; 32(2):284-5. PubMed ID: 22388156
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.
    Gopal S; Hough DW; Xu H; Lull JM; Gassmann-Mayer C; Remmerie BM; Eerdekens MH; Brown DW
    Int Clin Psychopharmacol; 2010 Sep; 25(5):247-56. PubMed ID: 20389255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone-related Pisa syndrome.
    Teng PR; Lai TJ
    J Clin Psychopharmacol; 2013 Feb; 33(1):129-31. PubMed ID: 23288235
    [No Abstract]   [Full Text] [Related]  

  • 20. Early-onset tardive dyskinesia in a neuroleptic-naive patient exposed to paliperidone.
    Hsu WY; Chiu NY
    J Clin Psychopharmacol; 2013 Oct; 33(5):712-3. PubMed ID: 23899637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.